Oncology Institute (TOCI) Price Target Raised to $7 by Needham
Published on 6/17/2026

AI Summary
Summarized by AI from the source belowNeedham has raised its price target for Oncology Institute (TOCI) to $7, reflecting a positive growth outlook. This adjustment indicates confidence in the company's future performance and may influence investor sentiment. The raised target suggests a potential upside, which could affect market activity around TOCI shares. Analysts are highlighting the company's growth prospects as a key factor behind the revised target.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
Related News

Earnings
Vertiv (VRT) Stock Falls 17% Despite Beating Q2 Earnings Expectations
Aug 1

Earnings
NextEra Energy (NEE) Increases Dividend Yield to 2.8% Amid Acquisition
Aug 1

Earnings
Vanguard VONG vs VBK: Small Cap ETF Offers 0.4% Yield in 2026
Aug 1

Earnings
TLTW and LQDW Bond ETFs Pay Over 12% Annual Distribution Yields
Aug 1